GENERIC NAME: metformin and sitagliptin
BRAND NAME: Janumet
DRUG CLASS AND MECHANISM: Janumet is a combination of two drugs, metformin and sitagliptin, that are used for reducing blood glucose (sugar) levels in individuals with type 2 diabetes. The FDA approved Janumet in March 2007.
Insulin is a hormone produced by the pancreas. It limits blood glucose levels by reducing the amount of glucose released by the liver into the blood and by increasing the removal of glucose from blood by muscle and fat tissues. Type 2 diabetes results when there is reduced sensitivity of muscle and fat to the effects of insulin. When the diabetes progresses, the pancreas produces less insulin. Both defects result in increased levels of glucose in the blood.
Metformin is an oral medication that lowers blood glucose by increasing the sensitivity of liver, muscle, fat, and other tissues to the effects of insulin. Increasing the sensitivity of tissues to insulin causes more glucose to be removed from blood and thereby reduces the level of glucose in the blood. In scientific studies, metformin reduced the complications of diabetes such as heart disease, blindness and kidney disease.
Quick GuideDiabetes Diet: Healthy Meal Plans for Diabetes-Friendly Eating
Report Problems to the Food and Drug Administration
You are encouraged to report negative side effects of prescription drugs to the FDA. Visit the FDA MedWatch website or call 1-800-FDA-1088.
Need help identifying pills and medications?
Use the pill identifier tool on RxList.